<SEC-DOCUMENT>0001437749-15-021911.txt : 20151209
<SEC-HEADER>0001437749-15-021911.hdr.sgml : 20151209
<ACCEPTANCE-DATETIME>20151209093733
ACCESSION NUMBER:		0001437749-15-021911
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20151208
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20151209
DATE AS OF CHANGE:		20151209

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			GeoVax Labs, Inc.
		CENTRAL INDEX KEY:			0000832489
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731]
		IRS NUMBER:				870455038
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-52091
		FILM NUMBER:		151277603

	BUSINESS ADDRESS:	
		STREET 1:		1900 LAKE PARK DRIVE
		STREET 2:		SUITE 380
		CITY:			SMYRNA
		STATE:			2Q
		ZIP:			30080
		BUSINESS PHONE:		678-384-7220

	MAIL ADDRESS:	
		STREET 1:		1900 LAKE PARK DRIVE
		STREET 2:		SUITE 380
		CITY:			SMYRNA
		STATE:			2Q
		ZIP:			30080

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Geovax Labs, Inc.
		DATE OF NAME CHANGE:	20061002

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	DAUPHIN TECHNOLOGY INC
		DATE OF NAME CHANGE:	19940826

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SUCCESSO INC
		DATE OF NAME CHANGE:	19910410
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>govx20151208_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD><TITLE>govx20151208_8k.htm</TITLE>
<!-- Created by RDG HTML Converter -->
</HEAD>
<BODY style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 10px; MARGIN-RIGHT: 10px">
<P id=PARA1 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"></FONT>&nbsp;</P>
<HR style="MARGIN-BOTTOM: 2px; BORDER-TOP: medium none; HEIGHT: 3px; BORDER-RIGHT: medium none; WIDTH: 100%; BORDER-BOTTOM: medium none; COLOR: #000000; BORDER-LEFT: medium none; MARGIN-TOP: 0px; BACKGROUND-COLOR: #000000">

<HR style="BORDER-TOP: medium none; HEIGHT: 1px; BORDER-RIGHT: medium none; WIDTH: 100%; BORDER-BOTTOM: medium none; POSITION: relative; COLOR: #000000; BORDER-LEFT: medium none; MARGIN-TOP: 0px; TOP: 0px; BACKGROUND-COLOR: #000000">

<P id=PARA3 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 18pt; FONT-FAMILY: Times New Roman, Times, serif"><B>SECURITIES AND EXCHANGE COMMISSION </B></FONT></P>
<P id=PARA4 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>WASHINGTON, D.C. 20549 </B></FONT></P>
<P id=PARA5 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<HR style="BORDER-TOP: medium none; HEIGHT: 1px; BORDER-RIGHT: medium none; WIDTH: 15%; BORDER-BOTTOM: medium none; COLOR: #000000;  BORDER-LEFT: medium none; BACKGROUND-COLOR: #000000" align="center">

<P id=PARA7 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B></B></FONT></P>
<P id=PARA9 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 18pt; FONT-FAMILY: Times New Roman, Times, serif"><B>FORM 8-K </B></FONT></P>
<P id=PARA10 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA11 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>CURRENT REPORT </B></FONT></P>
<P id=PARA12 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Pursuant to Section 13 or 15(d) of the </B></FONT></P>
<P id=PARA13 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Securities Exchange Act of 1934 </B></FONT></P>
<P id=PARA14 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA15 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Date of report (Date of earl</B><B>iest event reported): December 8</B><B>, 201</B><B>5</B></FONT></P>
<P id=PARA16 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<HR style="BORDER-TOP: medium none; HEIGHT: 1px; BORDER-RIGHT: medium none; WIDTH: 15%; BORDER-BOTTOM: medium none; COLOR: #000000;  BORDER-LEFT: medium none; BACKGROUND-COLOR: #000000" align="center">

<P id=PARA17 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"></FONT><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"></FONT>&nbsp;</P>
<P id=PARA19 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 18pt; FONT-FAMILY: Times New Roman, Times, serif"><B>GEOVAX LABS, INC.</B></FONT></P>
<P id=PARA20 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>(Exact name of registrant as specified in </B><B>its c</B><B>harter) </B></FONT></P>
<P id=PARA21 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>&nbsp;</B></FONT></P>
<P id=PARA22 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA23 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<TABLE id=TBL35  style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px" cellSpacing=0 cellPadding=0 border=0>

<TR>
<TD style="WIDTH: 31.3%; VERTICAL-ALIGN: top">
<P id=PARA24 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Delaware</B></FONT></P></TD>
<TD style="WIDTH: 3%; VERTICAL-ALIGN: bottom">
<P id=PARA25 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P></TD>
<TD style="WIDTH: 31.3%; VERTICAL-ALIGN: top">
<P id=PARA26 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>000-52091</B></FONT></P></TD>
<TD style="WIDTH: 3%; VERTICAL-ALIGN: bottom">
<P id=PARA27 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P></TD>
<TD style="WIDTH: 31.3%; VERTICAL-ALIGN: top">
<P id=PARA28 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>87-0455038</B></FONT></P></TD></TR>
<TR>
<TD style="WIDTH: 31.3%; VERTICAL-ALIGN: top">
<P id=PARA29 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>(State or other jurisdiction of</B></FONT></P>
<P id=PARA30 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>incorporation or organization)</B></FONT></P></TD>
<TD style="WIDTH: 3%; VERTICAL-ALIGN: bottom">
<P id=PARA31 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P></TD>
<TD style="WIDTH: 31.3%; VERTICAL-ALIGN: top">
<P id=PARA32 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>(Commission File No.)</B></FONT></P></TD>
<TD style="WIDTH: 3%; VERTICAL-ALIGN: bottom">
<P id=PARA33 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P></TD>
<TD style="WIDTH: 31.3%; VERTICAL-ALIGN: top">
<P id=PARA34 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>(IRS Employee Identification No.)</B></FONT></P></TD></TR></TABLE>
<P id=PARA36 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA37 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>&nbsp;</B></FONT></P>
<P id=PARA38 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>1900 Lake Park Drive, Suite 380</B></FONT></P>
<P id=PARA39 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Smyrna, Georgia 30080</B></FONT></P>
<P id=PARA40 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>(Address of principal executive o</B><B>ffices)</B><B> (Zip code)</B><B> </B></FONT></P>
<P id=PARA41 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA42 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>&nbsp;</B></FONT></P>
<P id=PARA43 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>(678) 384-7220</B></FONT></P>
<P id=PARA44 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>(</B><B>Registrant&#8217;s t</B><B>elephone number</B><B>, including area code</B><B>) </B></FONT></P>
<P id=PARA45 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA46 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA47 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions.</FONT></P>
<P id=PARA48 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA49 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">[ &nbsp;] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</FONT></P>
<P id=PARA50 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA51 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">[ &nbsp;] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR240.14a-12)</FONT></P>
<P id=PARA52 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA53 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">[ &nbsp;] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)).</FONT></P>
<P id=PARA54 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA55 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">[ &nbsp;] Pre-commencement communications pursuant to Rule 13e-4&#169; under the Exchange Act (17 CFR 240.13(e)-4(c))</FONT></P>
<P style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25">&nbsp;</P>
<HR style="MARGIN-BOTTOM: 2px; BORDER-TOP: medium none; HEIGHT: 1px; BORDER-RIGHT: medium none; WIDTH: 100%; BORDER-BOTTOM: medium none; COLOR: #000000; BORDER-LEFT: medium none; MARGIN-TOP: 0px; BACKGROUND-COLOR: #000000">

<HR style="MARGIN-BOTTOM: 0px; BORDER-TOP: medium none; HEIGHT: 3px; BORDER-RIGHT: medium none; WIDTH: 100%; BORDER-BOTTOM: medium none; POSITION: relative; COLOR: #000000; BORDER-LEFT: medium none; MARGIN-TOP: 0px; TOP: 0px; BACKGROUND-COLOR: #000000">

<DIV id=PGBK57  style="WIDTH: 100%; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<DIV id=PGFTR57  style="WIDTH: 100%; TEXT-ALIGN: center">&nbsp;</DIV>
<DIV id=PGNUM57  style="FONT-SIZE: 10pt; WIDTH: 100%; TEXT-ALIGN: center">&nbsp;</DIV>
<HR style="HEIGHT: 2px; WIDTH: 100%; PAGE-BREAK-AFTER: always; COLOR: #000000" noShade>

<DIV id=PGHDR57  style="WIDTH: 100%; TEXT-ALIGN: left">&nbsp;</DIV></DIV>
<P id=PARA57.2 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</FONT></P>
<P id=PARA58 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">This Form 8-K and other reports filed by GeoVax Labs, Inc. (the &#8220;Registrant&#8221;) from time to time with the Securities and Exchange Commission (collectively the &#8220;Filings&#8221;) contain forward looking statements and information that are based upon beliefs of, and information currently available to, the Registrant&#39;s management as well as estimates and assumptions made by the Registrant&#8217;s management. When used in the Filings the words &#8220;anticipate&#8221;, &#8220;believe&#8221;, &#8220;estimate&#8221;, &#8220;expect&#8221;, &#8220;future&#8221;, &#8220;intend&#8221;, &#8220;plan&#8221; or the negative of these terms and similar expressions as they relate to the Registrant or the Registrant&#8217;s management identify forward looking statements. Such statements reflect the current view of the Registrant with respect to future events and are subject to risks, uncertainties, assumptions and other factors relating to the Registrant&#8217;s industry, operations and results of operations and any businesses that may be acquired by the Registrant. Should one or more of these risks or uncertainties materialize, or should the underlying assumptions prove incorrect, actual results may differ significantly from those anticipated, believed, estimated, expected, intended or planned.</FONT></P>
<P id=PARA59 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>&nbsp;</B></FONT></P>
<P id=PARA60 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Item 8.01</B><B>&nbsp;&nbsp;&nbsp; &nbsp;&nbsp; &nbsp;</B><B>Other Events</B></FONT></P>
<P id=PARA61 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA62 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">On December 8, 2015 we issued a press release announcing our initiation of a new program to evaluate our MVA-VLP vaccine platform for use in cancer immunotherapy, and our entry into a Collaborative Research Agreement with the University of Pittsburgh for selection and testing of vaccine candidates.</FONT></P>
<P id=PARA63 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA64 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">A copy of the press release is filed herewith as Exhibit 99.1.</FONT></P>
<P id=PARA65 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>&nbsp;</B></FONT></P>
<P id=PARA66 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Item 9.01&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;Financial Statements and Exhibits. </B></FONT></P>
<P id=PARA67 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA68 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Exhibits </FONT></P>
<P id=PARA69 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA70 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B><U>Exhibit No.</U></B>&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;<B><U>Description of Exhibit</U></B></FONT></P>
<P id=PARA71 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA72 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Exhibit 99.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Press Release</FONT></P>
<P id=PARA73 style="TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 63pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -63pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"></FONT></P>
<DIV id=PGBK76  style="WIDTH: 100%; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<DIV id=PGFTR76  style="WIDTH: 100%; TEXT-ALIGN: center">&nbsp;</DIV>
<DIV id=PGNUM76  style="FONT-SIZE: 10pt; WIDTH: 100%; TEXT-ALIGN: center">2&nbsp;</DIV>
<HR style="HEIGHT: 2px; WIDTH: 100%; PAGE-BREAK-AFTER: always; COLOR: #000000" noShade>

<DIV id=PGHDR76  style="WIDTH: 100%; TEXT-ALIGN: left">&nbsp;</DIV></DIV>
<P id=PARA76.2 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</FONT><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B></B></FONT></P>
<P id=PARA78 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>SIGNATURE</B></FONT></P>
<P id=PARA79 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA80 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Current Report to be signed on its behalf by the undersigned hereunto duly authorized.</FONT></P>
<P id=PARA81 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA82 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Dated: December 9, 2015</FONT></P>
<P id=PARA83 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<TABLE id=TBL92  style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; WIDTH: 100%; TEXT-INDENT: 0px" cellSpacing=0 cellPadding=0 border=0>

<TR>
<TD vAlign=top width="50%">
<P id=PARA92.1 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</FONT></P></TD>
<TD vAlign=top width="38%" colSpan=2>
<P id=PARA92.2 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">GEOVAX LABS, INC.</FONT></P></TD>
<TD vAlign=top width="12%">
<P id=PARA92.3 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</FONT></P></TD></TR>
<TR>
<TD vAlign=top width="50%">&nbsp;</TD>
<TD vAlign=top width="38%" colSpan=2>&nbsp;</TD>
<TD vAlign=top width="12%">&nbsp;</TD></TR>
<TR>
<TD vAlign=top width="50%">
<P id=PARA92.4 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</FONT></P></TD>
<TD vAlign=top width="3%">
<P id=PARA92.5 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</FONT></P></TD>
<TD vAlign=top width="35%">
<P id=PARA92.6 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</FONT></P></TD>
<TD vAlign=top width="12%">
<P id=PARA92.7 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</FONT></P></TD></TR>
<TR>
<TD vAlign=top width="50%">
<P id=PARA92.8 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</FONT></P></TD>
<TD vAlign=top width="3%">
<P id=PARA92.9 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</FONT></P></TD>
<TD vAlign=bottom width="35%" noWrap align=left>
<P id=PARA92.10 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</FONT></P></TD>
<TD vAlign=top width="12%">
<P id=PARA92.11 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</FONT></P></TD></TR>
<TR>
<TD style="TEXT-ALIGN: left" vAlign=top width="50%" align=left>
<P id=PARA92.12 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</FONT></P></TD>
<TD style="TEXT-ALIGN: left" vAlign=top width="3%">
<P id=PARA92.13 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">By: </FONT></P></TD>
<TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=top width="35%" noWrap align=left>
<P id=PARA92.14 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp; /s/&nbsp;</FONT>Mark W. Reynolds </P></TD>
<TD vAlign=top width="12%">
<P id=PARA92.15 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</FONT></P></TD></TR>
<TR>
<TD vAlign=top width="50%">
<P id=PARA92.16 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</FONT></P></TD>
<TD vAlign=top width="3%">
<P id=PARA92.17 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</FONT></P></TD>
<TD vAlign=top width="35%">
<P id=PARA92.18 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Mark W. Reynolds </FONT></P></TD>
<TD vAlign=top width="12%">
<P id=PARA92.19 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</FONT></P></TD></TR>
<TR>
<TD vAlign=top width="50%">
<P id=PARA92.20 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</FONT></P></TD>
<TD vAlign=top width="3%">
<P id=PARA92.21 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</FONT></P></TD>
<TD vAlign=top width="35%">
<P id=PARA92.22 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Chief Financial Officer</FONT></FONT></P></TD>
<TD vAlign=top width="12%">
<P id=PARA92.23 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</FONT></P></TD></TR></TABLE>
<P id=PARA84 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 216pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"></FONT>&nbsp;</P>
<P id=PARA85 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25">&nbsp;</P>
<P style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25">3</P></BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML><HEAD><TITLE>ex99-1.htm</TITLE>
<!-- Created by RDG HTML Converter -->
</HEAD>
<BODY style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 10px; MARGIN-RIGHT: 10px">
<P id=PARA34 style="MARGIN-BOTTOM: 0px; TEXT-ALIGN: right; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Exhibit 99.1</B></FONT></P>
<P id=PARA35 style="MARGIN-BOTTOM: 0px; TEXT-ALIGN: left; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P><IMG src="img.jpg" width=199 height=53>
<P id=PARA1 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman, Times, serif"><B></B></FONT>&nbsp;</P>
<P id=PARA2 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman, Times, serif"><B>GeoVax </B><B>Begins Oncology Immunotherapy Program</B></FONT></P>
<P id=PARA3 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><I>&nbsp;</I></FONT></P>
<P id=PARA4 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><I>GeoVax to Apply its MVA-VLP Vaccine Technology to Cancer Immunotherapy</I></FONT></P>
<P id=PARA5 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><I>Collaborative Research Agreement Signed with University of Pittsburgh</I></FONT></P>
<P id=PARA6 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA7 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA8 style="TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>ATLANTA, GA, </B><B>December 8</B><B>, 2015 </B>&#8211; GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing innovative human vaccines, announced today that it has begun a new program to evaluate its MVA-VLP vaccine platform for use in cancer immunotherapy, and has entered into a Collaborative Research Agreement with the University of Pittsburgh for selection and testing of vaccine candidates.</FONT></P>
<P id=PARA9 style="TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA10 style="TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Currently cancer kills half of all men and one third of all women diagnosed in the United States. In 2015, it is estimated that more than half a million Americans will die from cancer<SUP style="vertical-align: baseline; position: relative; bottom:.33em;"> </SUP>and by 2025, the global burden will rise to 19.3 million new cases per year. Vaccination could be the most cost-effective medical intervention against cancer &#8211; especially in developing countries where mortality remains higher than in developed countries due to lack of early detection tools and access to treatment facilities.</FONT></P>
<P id=PARA11 style="TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA12 style="TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Certain tumor-associated antigens such as CEA (cancer embryonic antigen), PSA (prostate specific antigen) and MUC1 (cell surface associated mucin 1) are over-expressed (that is, produced in very large quantities) and aberrantly expressed (that is, produced in abnormal forms) in many advanced types of cancer. These antigens in the actual tumors are often recognized as abnormal by patients&#8217; immune systems but are not sufficiently immunogenic to trigger an effective immune response. The tumor antigens must be presented to the body in a different form, or in a different way, to enlist the immune system in fighting the cancer. GeoVax believes that its MVA-VLP platform may be able to do exactly this. With infectious disease targets like HIV and Ebola, the Company&#8217;s vaccine platform uses modified vaccinia Ankara (MVA) encoded with certain genes from viral targets, to support in vivo production of non-infectious virus-like particles (VLPs) from the cells of the person receiving the vaccine. Similarly, GeoVax believes that certain cancer antigens can be genetically modified and delivered using its MVA-VLP platform to train a patient&#8217;s own immune system to selectively seek and destroy those cells bearing such antigens. </FONT></P>
<P id=PARA13 style="TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA14 style="TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25; BACKGROUND-COLOR: #ffffff"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Harriet Robinson, Ph.D., GeoVax&#8217;s Chief Scientific Officer, commented, &#8220;We believe our MVA-VLP vaccine platform will allow co-expression of specific cancer antigens and immunomodulatory elements (if needed) tailored to induce a patient&#8217;s humoral and cellular responses to effectively target and destroy cancer cells. We expect our planned studies to further demonstrate the broad utility of our MVA vaccine vector beyond infectious diseases for a wide range of possible vaccines.&#8221;</FONT></P>
<P id=PARA15 style="TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25; BACKGROUND-COLOR: #ffffff"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA16 style="TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25; BACKGROUND-COLOR: #ffffff"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Robert T. McNally, Ph.D. GeoVax&#8217;s President and CEO, said, &#8220;This is an exciting new area for GeoVax. Our primary focus will continue to be infectious disease targets, as with our HIV and Ebola vaccine programs, but the application of our vaccine technology to oncology offers the prospect of addressing some very important unmet medical needs, as well as a significant opportunity to increase shareholder value. We are pleased to enter into a research collaboration with the University of Pittsburgh, which will screen our antigen-expressing vaccine candidates using monoclonal antibodies and select vaccines for testing in animal models. We intend to pursue additional collaborations with leading research institutions and others with novel cancer antigens or technologies suitable for use with our MVA-VLP platform.&#8221;</FONT></P>
<P id=PARA17 style="TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"></FONT></P>
<DIV id=PGBK36  style="WIDTH: 100%; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<DIV id=PGFTR36  style="WIDTH: 100%; TEXT-ALIGN: center">&nbsp;</DIV>
<DIV id=PGNUM36  style="FONT-SIZE: 10pt; WIDTH: 100%; TEXT-ALIGN: center">###&nbsp;</DIV>
<HR style="HEIGHT: 2px; WIDTH: 100%; PAGE-BREAK-AFTER: always; COLOR: #000000" noShade>

<DIV id=PGHDR36  style="WIDTH: 100%; TEXT-ALIGN: left">&nbsp;</DIV></DIV>
<P id=PARA36.2 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</FONT></P>
<P id=PARA18 style="TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25; BACKGROUND-COLOR: #ffffff"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>About GeoVax</B></FONT></P>
<P id=PARA19 style="TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25; BACKGROUND-COLOR: #ffffff"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA20 style="TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">GeoVax Labs, Inc. is a clinical-stage biotechnology company developing human vaccines against infectious diseases and cancer using its VLP vaccine platform. The Company&#8217;s most advanced development programs are focused on vaccines against Human Immunodeficiency Virus (HIV) and hemorrhagic fever viruses (Ebola, Marburg). GeoVax&#8217;s vaccine platform supports in vivo production of non-infectious virus-like particles (VLPs) from the cells of the person receiving the vaccine. The production of VLPs in the person being vaccinated mimics a natural infection, stimulating both the humoral and cellular arms of the immune system to recognize, prevent and control the target infection should it appear. </FONT></P>
<P id=PARA21 style="TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA22 style="TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25; BACKGROUND-COLOR: #ffffff"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Clinical trials for GeoVax&#8217;s preventive HIV vaccines have been conducted by the NIH-supported HIV Vaccine Trials Network (HVTN) with funding from the National Institute of Allergy and Infectious Disease (NIAID). Overall, GeoVax&#8217;s HIV vaccines, in various doses and combinations, have been tested in about 500 humans. For more information, go to www.geovax.com.</FONT></P>
<P id=PARA23 style="TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25; BACKGROUND-COLOR: #ffffff"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA24 style="TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><I><B>Forward-Looking Statements</B></I></FONT></P>
<P id=PARA25 style="TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA26 style="TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25; BACKGROUND-COLOR: #ffffff"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><I>Certain statements in this document are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act</I><I>.</I><I> These statements are based on management&#39;s current expectations and are subject to uncertainty and changes in circumstances. Actual results may differ materially from those included in these statements due to a variety of factors, including whether: GeoVax can develop and manufacture its vaccines with the desired characteristics in a timely manner, GeoVax&#39;s vaccines will be safe for human use, GeoVax&#39;s vaccines will effectively prevent HIV</I><I> or Ebola infection </I><I>in humans</I><I> or protect against cancer</I><I>, vaccines will receive regulatory approvals necessary to be licensed and marketed, GeoVax raises required capital to complete vaccine development, there is development of competitive products that may be more effective or easier to use than GeoVax&#39;s products, GeoVax will be able to enter into favorable manufacturing and distribution agreements, and other factors, over which GeoVax has no control. GeoVax assumes no obligation to update these forward-looking statements, and does not intend to do so. More information about these factors is contained in GeoVax&#39;s filings with the Securities and Exchange Commission including those set forth at "Risk Factors" in GeoVax&#39;s Form 10-K</I><I>.</I></FONT></P>
<P id=PARA27 style="TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><I>&nbsp;</I></FONT></P>
<P id=PARA28 style="TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Contact: </B></FONT></P>
<P id=PARA29 style="TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Robert T. McNally, Ph.D.</FONT></P>
<P id=PARA30 style="TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">GeoVax Labs, Inc.</FONT></P>
<P id=PARA31 style="TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">investor@geovax.com</FONT></P>
<P id=PARA32 style="TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">678-384-7220</FONT></P>
<P id=PARA33 style="TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P></BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>img.jpg
<TEXT>
begin 644 img.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1"  U ,<# 2(  A$! Q$!_\0
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M?[+?PR\3 _VE\.O FH;NOVG0+27/_?49H^M9:]Z#7I/_ #0_8XQ;54_^W?\
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MZHCG1O#M@5:_U1EX+ $XCB!P&E?"CH-S84_AA^VW_P %NOCI^VG<WE@VO2>
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M2BK+X5:WK8YJ\<MJ*51M.3\V?!?PK_:)U[X0?\&^/CS1=)OKJV@\8?%,>&Y
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M?[!W@WQI^R=J7QGT[2K+2/''@NYM?ME_:QB%]7LYIT@:.8KC>Z-*CHY^9=K
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A%B,0(D50DARC, U%%%>U.O.$(*+^RNQYT:492DWW/__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
